Merck and Sun sign pact

Tuesday, April 26, 2011 11:41 AM

Merck and India-based Sun Pharmaceutical Industries have collaborated regarding rights to Merck’s diabetes drug Januvia, according to Pharma Times.

Merck and Sun have signed “an India-specific strategic partnership agreement” which states Sun will have the right to market, promote and distribute the dipeptidyl peptidase-4 inhibitor Januvia (sitagliptin) and Janumet (sitagliptin plus metformin), under different brand names.

K.G. Ananthakrishnan, managing director of Merck, Sharp & Dohme in India, indicated that the partnership will increase access to diabetic drugs in a country with “high disease burden of type 2 diabetes.”

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs